This site is intended for health professionals only

NICE approves semaglutide for weight loss

NICE has recommended use of semaglutide with a reduced-calorie diet and increased physical activity as a therapeutic option for weight loss.

In a technology appraisal guidance, the UK’s NICE has recommended the use of semaglutide as part of a weight loss management strategy.

Obesity is a global health problem and the World Obesity Atlas 2023 report has estimated based on current trends, that overweight and obesity will affect over 4 billion people by 2035, reflecting an increase from 38% of the global population in 2020 to more than 50% in 2035.

Semaglutide (brand name Wegovy) has a current marketing authorisation ‘as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity), or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbidity.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in respiratory care at events delivered by renowned experts from CofE
Advertisement

Evidence for the effectiveness of the drug in weight loss was derived from the STEP 1 trial. This randomised, double-blind, placebo-controlled trial included nearly 2,000 adults with a body mass index (BMI) of 30 or more and individuals with a BMI of 27 but with ≥1 weight-related coexisting condition and who were not diabetic.

Participants received once weekly semaglutide 2.4 mg or placebo. After 68 weeks of treatment, participants receiving semaglutide saw a 14.9% mean decrease in their body weight compared to baseline compared to only 2.4% among placebo participants and this difference was statistically significant (p < 0.001).

Helen Knight, director of medicines evaluation at NICE, said: ‘Semaglutide won’t be available to everyone. Our committee has made specific recommendations to ensure it remains value for money for the taxpayer, and it can only be used for a maximum of two years.’

The 2019 Health Survey for England estimated that 28% of adults in England were obese and a further 36% were overweight and that Government estimates for the current NHS costs of obesity in the UK were £6.1 billion and £27 billion to wider society.






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x